A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain
Status:
Terminated
Trial end date:
2021-02-16
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to demonstrate the efficacy and safety of linzagolix
administered orally once daily for 3 months at a dose of 75 mg alone or of 200 mg in
combination with add-back hormone replacement therapy (ABT: estradiol (E2) 1 mg /
norethisterone acetate (NETA) 0.5 mg) versus placebo, in the management of moderate to severe
endometriosis-associated pain (EAP).